Tandem Diabetes Care Inc (TNDM) reported quarterly earnings results on Thursday, Apr-28-2016. The company said it had a profit of $-0.68 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.69. The company posted revenue of $20.06 million in the period, compared to analysts expectations of $17.64 million. The company’s revenue was up 63.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.83 EPS.
Many Wall Street Analysts have commented on Tandem Diabetes Care Inc. Tandem Diabetes Care Inc was Downgraded by BofA/Merrill to ” Underperform” on Mar 24, 2016.
Tandem Diabetes Care Inc opened for trading at $10.35 and hit $10.48 on the upside on Wednesday, eventually ending the session at $10.39, with a gain of 1.07% or 0.11 points. The heightened volatility saw the trading volume jump to 82,930 shares. Company has a market cap of $315 M.
In a different news, on Apr 22, 2016, John F Sheridan (EVP, CHIEF OPERATING OFFICER) sold 2,000 shares at $10.00 per share price. According to the SEC, on Aug 4, 2015, Howard E Jr Greene (director) sold 20,000 shares at $12.70 per share price.
Tandem Diabetes Care Inc. is a medical device company engaged in designing developing and commercializing products for people with insulin-dependent diabetes. The Company’s products include t:slim Insulin Delivery System (t:slim) and t:flex Insulin Delivery System (t:flex). The t:slim consists of the t:slim pump its 300-unit disposable insulin cartridge and an infusion set. The t:flex consists of the t:flex pump its 480-unit disposable insulin cartridge and an infusion set. The Company’s technology platform features Micro-Delivery Technology a miniaturized pumping mechanism which draws insulin from a flexible bag within the pump’s cartridge rather than relying on a syringe and plunger mechanism.